149 related articles for article (PubMed ID: 25026175)
1. Copy number analysis of 24 oncogenes: MDM4 identified as a putative marker for low recurrence risk in non muscle invasive bladder cancer.
Salvi S; Calistri D; Gurioli G; Carretta E; Serra L; Gunelli R; Zoli W; Casadio V
Int J Mol Sci; 2014 Jul; 15(7):12458-68. PubMed ID: 25026175
[TBL] [Abstract][Full Text] [Related]
2. Semi-comprehensive analysis of gene amplification in thymic malignant tumors using multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
Kakegawa S; Matsumoto I; Tamura M; Takata M; Yoshida S; Saito D; Tanaka Y; Takemura H; Ooi A
Int J Clin Exp Pathol; 2020; 13(5):1035-1044. PubMed ID: 32509076
[TBL] [Abstract][Full Text] [Related]
3. Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer.
Kriegmair MC; Balk M; Wirtz R; Steidler A; Weis CA; Breyer J; Hartmann A; Bolenz C; Erben P
Anticancer Res; 2016 Oct; 36(10):5205-5213. PubMed ID: 27798881
[TBL] [Abstract][Full Text] [Related]
4. High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.
Veerakumarasivam A; Scott HE; Chin SF; Warren A; Wallard MJ; Grimmer D; Ichimura K; Caldas C; Collins VP; Neal DE; Kelly JD
Clin Cancer Res; 2008 May; 14(9):2527-34. PubMed ID: 18451213
[TBL] [Abstract][Full Text] [Related]
5. Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.
Cao L; Basudan A; Sikora MJ; Bahreini A; Tasdemir N; Levine KM; Jankowitz RC; McAuliffe PF; Dabbs D; Haupt S; Haupt Y; Lucas PC; Lee AV; Oesterreich S; Atkinson JM
Cancer Lett; 2019 Oct; 461():21-30. PubMed ID: 31229512
[TBL] [Abstract][Full Text] [Related]
6. DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach.
Casadio V; Molinari C; Calistri D; Tebaldi M; Gunelli R; Serra L; Falcini F; Zingaretti C; Silvestrini R; Amadori D; Zoli W
J Exp Clin Cancer Res; 2013 Nov; 32(1):94. PubMed ID: 24252461
[TBL] [Abstract][Full Text] [Related]
7. Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature.
Koelsche C; Benhamida JK; Kommoss FKF; Stichel D; Jones DTW; Pfister SM; Heilig CE; Fröhling S; Stenzinger A; Buslei R; Mentzel T; Baumhoer D; Ladanyi M; Antonescu CR; Flucke U; Gorp JV; Bode-Lesniewska B; Deimling AV; Mechtersheimer G
Mod Pathol; 2021 Dec; 34(12):2122-2129. PubMed ID: 34312479
[TBL] [Abstract][Full Text] [Related]
8. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
[TBL] [Abstract][Full Text] [Related]
9. Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy.
Soave A; Kluwe L; Yu H; Rink M; Gild P; Vetterlein MW; Marks P; Sauter G; Fisch M; Meyer CP; Ludwig T; Dahlem R; Minner S; Pantel K; Steinbach B; Schwarzenbach H
Sci Rep; 2020 Dec; 10(1):21562. PubMed ID: 33298978
[TBL] [Abstract][Full Text] [Related]
10. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
11. Copy number aberrations using multicolour fluorescence in situ hybridization (FISH) for prognostication in non-muscle-invasive bladder cancer (NIMBC).
Matsuyama H; Ikemoto K; Eguchi S; Oga A; Kawauchi S; Yamamoto Y; Kawai Y; Matsumoto H; Hara T; Nagao K; Sakano S; Sasaki K
BJU Int; 2014 Apr; 113(4):662-7. PubMed ID: 23890221
[TBL] [Abstract][Full Text] [Related]
12. Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations: effect of a prospective intervention in primary bladder cancer patients.
Sörenby A; Baseckas G; Bendahl PO; Brändstedt J; Håkansson U; Nilsson S; Patschan O; Tinzl M; Wokander M; Liedberg F; Gudjonsson S
Scand J Urol; 2019; 53(2-3):109-115. PubMed ID: 31064253
[No Abstract] [Full Text] [Related]
13. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
[TBL] [Abstract][Full Text] [Related]
14. Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification.
Kornegoor R; Moelans CB; Verschuur-Maes AH; Hogenes MC; de Bruin PC; Oudejans JJ; Marchionni L; van Diest PJ
Breast Cancer Res Treat; 2012 Aug; 135(1):49-58. PubMed ID: 22527098
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Urinary DNA Methylation as a Marker for Recurrent Bladder Cancer: A 2-Center Prospective Study.
Shindo T; Shimizu T; Nojima M; Niinuma T; Maruyama R; Kitajima H; Kai M; Itoh N; Suzuki H; Masumori N
Urology; 2018 Mar; 113():71-78. PubMed ID: 29196070
[TBL] [Abstract][Full Text] [Related]
17. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O
Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443
[TBL] [Abstract][Full Text] [Related]
18. Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer.
Le Goux C; Vacher S; Schnitzler A; Barry Delongchamps N; Zerbib M; Peyromaure M; Sibony M; Allory Y; Bieche I; Damotte D; Pignot G
Sci Rep; 2020 Oct; 10(1):16641. PubMed ID: 33024200
[TBL] [Abstract][Full Text] [Related]
19. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
[TBL] [Abstract][Full Text] [Related]
20. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]